Resverlogix Corp. Provides Bi-Weekly MCTO Status Update

• On April 2, 2026, the Alberta Securities Commission (ASC) formally issued a Management Cease Trade Order (MCTO) against Resverlogix Corp.
• The order was triggered by the company's failure to file its audited FY2025 financial statements, Annual Information Form, and MD&A by the March 31, 2026 regulatory deadline.
• The MCTO restricts the CEO and CFO from trading company securities until the filings are completed and the order is lifted. All other insiders remain under a standard blackout. Public shareholders retain unrestricted trading rights.
• Management projects completion of the audit and filing by April 10, 2026, but explicitly states this timeline is not guaranteed.
• The company confirms it is not currently subject to insolvency proceedings and states no other material business changes have occurred since the November 2025 interim report.
• This release is the direct procedural follow-through to the March 17 delay announcement and the March 31 MCTO application.

• The MCTO issuance is a regulatory formality that was fully telegraphed by prior company disclosures. It does not introduce new operational or clinical information.
• The restriction on executive trading is a standard penalty under National Policy 12-203 and does not halt public market liquidity.
• The true material impact lies in the underlying cause: an auditor's inability to complete the FY2025 audit on time. This strongly suggests unresolved accounting complexities, potential going-concern qualifications, or disputes over asset valuations and debt classifications.
• Given the company's extreme balance sheet deficiency and reliance on related-party debt, the audit delay compounds existing solvency concerns. The market has likely priced in this regulatory friction, resulting in a muted immediate price reaction.

• Resverlogix Corp. is a clinical-stage biotechnology company historically focused on developing epigenetic therapies, primarily targeting cardiovascular and metabolic diseases through BET protein inhibition.
• The company's lead candidate, apabetalone (RVX-208), has undergone multiple Phase 2 and Phase 3 trials over the past decade.
• Recent disclosures contain zero updates on clinical trial progress, regulatory submissions, or commercial partnerships. Corporate communications are entirely consumed by financial compliance and audit delays.
• The lack of recent pipeline catalysts suggests the company is in a holding pattern, prioritizing balance sheet survival over active clinical development.